Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01103414 · ClinicalTrials.gov registry record · Phase 2
Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of Mitoglitazone in Type 2 Diabetic Patients
A Phase 2 study of Type 2 Diabetes, sponsored by Metabolic Solutions Development Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 356
- Enrollment target
- 20
- Study locations
NCT01103414: Completed Phase 2 study of Type 2 Diabetes, sponsored by Metabolic Solutions Development Company.
NCT01103414 is a Phase 2 study of Type 2 Diabetes that has completed, run by Metabolic Solutions Development Company. The registered enrollment target is 356 participants, below the 3,923-participant average among 327 other Type 2 Diabetes trials with a reported enrollment target (91% lower). The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01103414, a Phase 2 study of Type 2 Diabetes, has completed, sponsored by Metabolic Solutions Development Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 356 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the safety, tolerability and efficacy of three dose levels of Mitoglitazone™ (MSDC-0160) in patients with type 2 diabetes.
Primary Outcome
Change from baseline in fasting plasma glucose in response to three different doses of Mitoglitazone as compared to pioglitazone following once-daily dosing for 84 consecutive days (12 weeks) in patients with Type 2 diabetes.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Pioglitazone
- DRUG Mitoglitazone
Study Locations (20)
California
- - Chino
- - Los Angeles
- - Spring Valley
- - Walnut Creek
Florida
- - Miami
- - New Port Richley
- - Palm Harbor
- - Pembroke Pines
Ohio
- - Cincinnati
- - Kettering
- - Tiffin
Alabama
- - Huntsville
- - Muscle Shoals
Oregon
- - Eugene
- - Portland
Georgia
- - Marietta
Illinois
- - Chicago
Indiana
- - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 356 participants |
| Start Date | 2010-09 |
| Est. Completion | 2011-12 |
| Phase | Phase 2 |
What the finished NCT01103414 record still lists
NCT01103414 is an interventional study that assigns participants to a tested intervention. The registered 356 participants enrollment target is mid-sized for trials with a published cap, below the 3,923-participant average among 327 other Type 2 Diabetes trials with a reported enrollment target (91% lower).
The record links to 1 condition, with Type 2 Diabetes appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT01103414 names 20 study sites across 10 states, led by California, Florida, Ohio.
Frequently Asked Questions
What is clinical trial NCT01103414 about?
NCT01103414 is a clinical study titled "Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of Mitoglitazone in Type 2 Diabetic Patients". The purpose of this study is to evaluate the safety, tolerability and efficacy of three dose levels of Mitoglitazone™ (MSDC-0160) in patients with type 2 diabetes.
What is the current status of trial NCT01103414?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 356 participants. The study started on 2010-09. Estimated completion is 2011-12.
What conditions does trial NCT01103414 study?
This clinical trial studies the following conditions: Type 2 Diabetes.
What interventions are being tested in trial NCT01103414?
The interventions under investigation include: Placebo (DRUG), Pioglitazone (DRUG), Mitoglitazone (DRUG).
Who is sponsoring clinical trial NCT01103414?
This trial is sponsored by Metabolic Solutions Development Company, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01103414 being conducted?
This trial has 20 study locations across Alabama, California, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 2 Diabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01103414's enrollment target sits among peer trials
356 56th of 327 higher than 272 of 327 other Type 2 Diabetes trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Type 2 Diabetes trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Renal Mechanism of SGLT2 Inhibition
RECRUITING · Phase 2
-
A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide
RECRUITING · Phase 2
-
The Effect of Glycemic Control and of GLP-1 Receptor Agonism on Islet GLP-1 in People With Type 1 and Type 2 Diabetes
RECRUITING · Phase 2
-
Trial Against INtractable Type 2 Diabetes (CAPTAIN-T2D)
RECRUITING · Phase 2
-
NAD Augmentation in Diabetes Kidney Disease
RECRUITING · Phase 2
-
The Effects of Glucagon on Hepatic Metabolism in People With Type 2 Diabetes After Caloric Restriction
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06077838 · 356 participants · NA
RELAXaHEAD for Headache Patients (Phase III)
- NCT06293469 · 356 participants · NA
Accelerated Flap Coverage in Severe Lower Extremity Trauma
- NCT06958328 · 356 participants · Phase 3
Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer
- NCT06960993 · 356 participants · NA
Mosaic Trial for Stem Cell Transplant Recipients
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia